Pyxis Oncology Inc PYXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PYXS is a good fit for your portfolio.
News
-
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
-
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
-
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
-
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
-
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
-
Pyxis Oncology Announces $50 Million Private Placement
Trading Information
- Previous Close Price
- $4.30
- Day Range
- $4.25–4.42
- 52-Week Range
- $1.35–6.85
- Bid/Ask
- $4.30 / $4.56
- Market Cap
- $249.97 Mil
- Volume/Avg
- 164,540 / 783,813
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 50
- Website
- https://www.pyxisoncology.com
Comparables
Valuation
|
Metric
|
PYXS
|
CLDX
|
ANAB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.53 | 4.73 | 5.82 |
Price/Sales | — | 255.51 | 30.24 |
Price/Cash Flow | — | — | — |
Price/Earnings
PYXS
CLDX
ANAB
Financial Strength
|
Metric
|
PYXS
|
CLDX
|
ANAB
|
|---|---|---|---|
Quick Ratio | 4.63 | 13.69 | 10.62 |
Current Ratio | 4.84 | 13.87 | 10.87 |
Interest Coverage | — | — | −9.09 |
Quick Ratio
PYXS
CLDX
ANAB
Profitability
|
Metric
|
PYXS
|
CLDX
|
ANAB
|
|---|---|---|---|
Return on Assets (Normalized) | −30.57% | −30.49% | −23.50% |
Return on Equity (Normalized) | −39.37% | −33.19% | −75.96% |
Return on Invested Capital (Normalized) | −38.46% | −32.85% | −68.56% |
Return on Assets
PYXS
CLDX
ANAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vzlldcwr | Jszn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wvmbpww | Gvlnnkq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Htfwqntfs | Phkwkp | $97.8 Bil | |
MRNA
| Moderna Inc | Wckzjrjd | Fhgf | $41.3 Bil | |
ARGX
| argenx SE ADR | Rzpvrzgdl | Kfnsk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zjlwfmq | Dchg | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bpxmjcbjr | Bppxhr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Znrrkgzhp | Ppxxwwc | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xbdnggtlw | Cxdgyb | $12.5 Bil | |
INCY
| Incyte Corp | Xclwmbpfb | Zjxfj | $11.6 Bil |